Outlook Therapeutics, Inc.
OTLK
$0.38
$0.026.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -102.86M | -62.42M | -43.44M | 21.12M | -46.81M |
| Total Depreciation and Amortization | 118.30K | 117.00K | 116.10K | 115.40K | 114.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.78M | 4.06M | -20.48M | -88.69M | -28.10M |
| Change in Net Operating Assets | -2.84M | 6.41M | 7.37M | 3.41M | 8.07M |
| Cash from Operations | -55.80M | -51.83M | -56.43M | -64.05M | -66.73M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 33.10M | 33.10M | 33.10M | 33.10M | -- |
| Total Debt Repaid | -36.14M | -36.14M | -33.82M | -32.91M | -1.10K |
| Issuance of Common Stock | 61.82M | 48.03M | 34.14M | 24.30M | 62.19M |
| Repurchase of Common Stock | -- | -- | -115.00K | -115.00K | -115.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 58.78M | 44.99M | 33.31M | 24.37M | 62.07M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.97M | -6.84M | -23.12M | -39.67M | -4.65M |